You are here
Formulari Ubat KKM (FUKKM)
| # | Generic Name | MDC | Category | Indications | Pres. Restrictions | Dosage |
|---|---|---|---|---|---|---|
| 751 | Hydrocortisone 1% Cream | D07AA02-000-G10-01-XXX | B | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | None | Apply sparingly to the affected area. Adult: 3-4 times daily. Children: 1-2 times daily |
| 752 | Hydrocortisone 1% Ointment | D07AA02-000-G50-01-XX | B | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | None | Apply sparingly to the affected area. Adult: 3-4 times daily. Children: 1-2 times daily |
| 753 | Hydrocortisone 10mg Tablet | H02AB09-000-T10-01-XXX | B | i) Glucocorticoid replacement therapy in primary or secondary adrenal insufficiencies ii) Congenital adrenal hyperplasia in children | None | ADULT: 20 - 30 mg daily in divided doses. CHILD: 10-15mg/m2/day in 3 divided dose The dosing is individualized according to product insert / protocol |
| 754 | Hydrocortisone Sodium Succinate 100mg Injection | H02AB09-520-P40-01-XXX | C | Conditions responsive to systemic or local glucocorticoid injection therapy. | None | ADULT: Initially 100 - 500 mg IV over 30 seconds to more than 10 minutes. Dose may be repeated at intervals of 2, 4 or 6 hours CHILD: 2-4mg/kg/dose every 6 hourly. The dosing is individualized according to product insert / protocol |
| 755 | Hydrogen Peroxide 20 volume Solution | D08AX01241L9901XX | C | Skin disinfection, particularly cleansing and deodorising wounds and ulcers | Hydrogen Peroxide 6% (=approx. 20 vol) shall be dispensed. For cleansing wounds: 1.5% to 6% solution apply 2-3 times daily or when necessary. As a mouthwash: rinse the mouth for 2-3 minutes with 15ml of hydrogen peroxide 6% diluted in half a tumblerful of warm water 2-3 times daily. Disinfecting cleaned equipment: immersion for 30 minutes in 6% solution. As ear drop for removal of wax: hydrogen peroxide 6% diluted with 3 parts of water preferably just before use | |
| 756 | Hydroxychloroquine Sulphate 200 mg Tablet | P01BA02-183-T10-01-XXX | A | i) SLE and mixed connective tissue disease for skin, joint and serosa ii) Second line therapy for acute rheumatoid arthritis | None | i) Initially 400 mg daily in divided dose. Maintenance : 200 - 400 mg daily ii) ADULT : 400 - 600 mg daily. Maintenance: 200 - 400 mg daily. CHILD : up to 6.5 mg/kg daily (maximum 400mg daily) |
| 757 | Hydroxyethyl Cellulose Jelly | V07AY00250G4001XX | B | For lubricating purpose | Apply sufficiently for lubricating purpose | |
| 758 | Hydroxyethyl Starch 6% Injection | B05AA07000P9901XX | B | Therapy and prophylaxis of hypovolaemia and shock in connection with surgery trauma, infections and burns | ADULT daily dose up to 20 ml/kg/day. Normally 500-1500 ml. The rate of infusion may approach 20 ml/kg/hour in acute haemorrhagic shock, slower rates in burns and septic shock. CHILD under 10 years do not exceed 15 ml /kg/hour. | |
| 759 | Hydroxyprogesterone Caproate 250mg/ml Injection | G03DA03-128-P20-01-XXX | A | Habitual abortion | None | IM: 250-500mg weekly as soon as pregnancy has been confirmed by diagnosis. |
| 760 | Hydroxyurea 500 mg Capsule | L01XX05-000-C10-01-XXX | A | i)Solid tumours ii) Chronic myelocytic leukaemia and myeloproliferative disease | - | i) Intermittent therapy: 80 mg/kg orally as a single dose every 3rd day. Continuous therapy: 20 - 30 mg/kg orally as a single dose dly. Concomitant therapy with irradiation: 80 mg/kg orally as a single dose every 3rd day (administration of hydroxyurea should be started at least 7 days before initiation of irradiation and continued during radiotherapy as well). ii) Continuous therapy 20 - 30 mg/kg orally as a single dose daily |
| 761 | Hydroxyzine HCl 25mg Tablet | N05BB01110T1001XX | A | Allergic pruritus | Initially 25 mg at night, increased if necessary up to 25 mg 3-4 times daily. ADULT and CHILD more than 10 years : 50 - 75 mg; 6 - 10 years: 25 - 50 mg; 2 - 5 years: 12.5 - 25 mg; to be taken daily in divided doses | |
| 762 | Hyoscine N-Butylbromide 10mg Tablet | A03BB01-320-T10-01-XXX | C | Gastrointestinal tract and genito-urinary tract spasm, dyskinesia of the biliary system. | Medical Assistant in health settings without Medical Officer is allowed to prescribe this medicine for adult use only. | ADULT 10-20mg, 3-4 times a day. CHILD 6-12 years old: 10mg 3 times a day. |
| 763 | Hyoscine N-Butylbromide 1mg/ml Liquid | A03BB01-320-L50-01-XX | B | Gastrointestinal tract and genito-urinary tract spasm, dyskinesia of the biliary system | None | ADULT 10-20mg, 3-4 times a day. CHILD 6-12 years old: 10mg 3 times a day. |
| 764 | Hyoscine N-Butylbromide 20mg/ml Injection | A03BB01-320-P30-01-XXX | B | Gastrointestinal tract and genito-urinary tract spasm, dyskinesia of the biliary system | None | ADULT: 20 mg IM/IV repeated after 30 min if needed. Max: 100 mg daily. Not recommended for CHILD below 12 years. Dosing is individualised and according to product insert/protocol |
| 765 | Ibandronic Acid 150mg Tablet | M05BA06000T1003XX | A* | Treatment of postmenopausal osteoporosis to reduce the risk of fracture. Review treatment after 2 years and if there is positive response, treatment may be continued up to 5 years and then re-evaluate. Treatment should be stopped if there is no positive response after 5 years. Otherwise, patient needs to be given drug holiday for 1 to 2 years and then continue treatment shall the benefit outweigh the risk. | 150 mg once monthly | |
| 766 | Ibuprofen 100mg/5ml Suspension | M01AE01-000-L80-01-XXX | B | i. Anti-inflammatory for rheumatic disease ii. Analgesic for treatment of mild to moderate pain | Not indicated in fever due to infection | Children: 5 - 10 mg/kg/dose (max 2.4 gm/day) every 6-8 hourly. Not recommended for <7kg |
| 767 | Ibuprofen 200 mg Tablet | M01AE01000T1001XX | B | Pain and inflammation in rheumatic disease | None | Dosage: ADULT : 200 - 400 mg 3 times daily after food, maximum 3.2 g daily. CHILD : 30-50 mg/kg body weight daily in divided doses, maximum 2.4g daily. Lowest effective dose for the shortest possible duration. |
| 768 | Idarubicin 1mg/mL Injection | L01DB06110P4002XX | A* | i) Acute non-lymphocytic leukemia (ANLL) in adults for remission induction in untreated patients or for remission induction in relapsed or refractory patients. ii) Acute lymphocytic leukemia (ALL) as second line treatment in adult and children. | i) Adult: 12mg/m2 IV daily for 3 days in combination with cytarabine. Idarubicin may also be administered as a single agent and in combination, at a dose of 8mg/m2 IV daily for 5 days. ii) Adult: 12mg/m2 IV daily for 3 days as a single agent. Children: 10mg/m2 IV daily for 3 days as a single agent. All of these dosages should take into account the hematological status of the patient and the dosages of other cytotoxic drugs when used in combination. | |
| 769 | Idarucizumab 50 mg/ml solution for injection/infusion | V03AB37-000-P30-01-XXX | A* | Idarucizumab is a specific reversal agent for dabigatran and is indicated in patients treated with dabigatran when rapid reversal of the anticoagulant effects of dabigatran is required: i. For emergency surgery/urgent procedures ii. In life-threatening or uncontrolled bleeding | To be prescribed by cardiologist, haematologist, general medicine physician, anaesthesiologist and emergency physician only | The recommended dose of Idarucizumab is 5 g (2 x 2.5 g/50 ml) to be administered intravenously, as two consecutive infusions over 5 to 10 minutes each or as a bolus injection. |
| 770 | Idursulfase 2mg/ml Injection | A16AB09000P3001XX | A* | Hunter syndrome (Mucopolysaccharidosis II, MPS II). | 0.5 mg/kg of body weight administered every week as an intravenous infusion. | |
| 771 | Ifosfamide 1 g Injection | L01AA06000P4001XX | A* | i) Solid tumours ii) Leukaemia iii) Lymphoma | i) 1.2 - 2.4 g/m2/day for 3 - 7 days as a 30 - 120 minutes infusion. Alternatively, can also be given as a single high dose, eg. 5 g/m2 in a 24 hour infusion. Cycles may be repeated every 3 - 4 weeks ii) CHILD: 400 - 3000 mg/m2/day for 3 - 5 days according to protocol iii) Refer to protocols | |
| 772 | Imatinib Mesylate 100mg Tablet | L01XE01-196-T10-01-XXX | A* | i) ADULT and CHILD: Philadelphia positive (Ph+) chronic myeloid leukaemia in chronic phase and in early acceleration after failure of interferon therapy ii) Treatment of patients with unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST) who are positive for CD117/c-kit | i) ADULT: Chronic phase chronic myeloid leukemia: 400 mg once daily. Accelerated phase or blast crisis chronic myeloid leukemia: 600 mg once daily. CHILD more than 2 years, chronic and advanced phase chronic myeloid leukemia: 340 mg/m2 daily. Max: 800 mg/day ii) ADULT : 400mg/day | |
| 773 | Imatinib Mesylate 400mg Tablet | L01XE01-196-T10-02-XXX | A* | i) ADULT and CHILD: Philadelphia positive (Ph+) chronic myeloid leukaemia in chronic phase and in early acceleration after failure of interferon therapy ii) Treatment of patients with unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST) who are positive for CD117/c-kit | i) ADULT: Chronic phase chronic myeloid leukemia: 400 mg once daily. Accelerated phase or blast crisis chronic myeloid leukemia: 600 mg once daily. CHILD more than 2 years, chronic and advanced phase chronic myeloid leukemia: 340 mg/m2 daily. Max: 800 mg/day ii) ADULT : 400mg/day | |
| 774 | Imiglucerase 400IU Injection | A16AB02000P4002XX | A* | Non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease and who exhibit clinically significant non-neurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: - anemia, after exclusion of other causes, such as iron deficiency - thrombocytopenia - bone disease, after exclusion of other causes, such as Vitamin D deficiency - hepatomegaly or splenomegaly | Dosage should be individualized to each patient. Initial dosages range from 2.5 units/kg of body weight 3 times a week to 60 units/kg once every 2 weeks. Administered by intravenous infusion over 1-2 hours. | |
| 775 | Imipenem 500mg and Cilastatin 500mg Injection | J01DH51-961-P40-02-XXX | A* | Severe infections caused by susceptible pathogens especially useful in infections involving ESBL organisms. Not to be used for prophylaxis | None | Based on type or severity of infection, susceptibility of pathogen(s) and patient condition including body weight and renal function. ADULT: 1 - 2 g/day in 3 - 4 divided doses. Maximum: 4 g/day or 50 mg/kg/day. Infusion rate: less than 500 mg dose: over 20 - 30 minutes, more than 500 mg: dose over 40 - 60 minutes. CHILDREN: ≥ 40kg body weight should receive adult doses. CHILDREN AND INFANTS: <40kg body weight should receive 15mg/kg at six hour intervals. The total daily dose should not exceed 2g. |
| 776 | Imiquimod 5 % w/w Cream | D06BB10000G1001XX | A* | Treatment of external genital and perianal warts or condyloma acuminata in adults | Apply to affected area at bedtime for 3 times a week for up to 16 weeks; leave on skin for 6-10 hours | |
| 777 | Immunoglobulin Tetanus Human 250 Units/Vial Injection | J06BB02000P3001XX | B | Passive immunization against tetanus | Prophylaxis of tetanus: IM 250 units. Treatment of tetanus: IM 30 - 300 units/kg | |
| 778 | Inclisiran 284 mg/1.5ml Solution for Injection in Pre-Filled Syringe | C10AX16-520-P50-01-xxx | A* | Inclisiran is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or • in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. | As a third-line therapy for: • Patient with history of ST-elevated myocardial infarction (STEMI) or non-ST elevated myocardial infarction (NSTEMI) AND • DM or target organ damage or >3 CV risk factors AND/OR CKD with eGFR<60mL/min/1.73 m2 AND • Unable to achieve LDL-C goal (<1.8mmol/L) or require 50% LDL-C reduction from baseline despite maximally tolerated dose of statin and ezetimibe; AND optimum adherence to statin and ezetimibe | The recommended dose is 284 mg inclisiran administered as a single subcutaneous injection: initially, again at 3 months, followed by every 6 months. |
| 779 | Indacaterol acetate/ glycopyrronium bromide/ mometasone furoate 150/50/160mcg inhalation powder hard capsules | R03AL12-986-A20-01-XXX | A | As a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year. | None | one capsule to be inhaled once daily. |
| 780 | Indacaterol Maleate 110mcg & Glycopyrronium Bromide 50mcg inhalation powder hard capsules | R03AL04-989-C11-01-XXX | A/KK | As a once-daily maintenance bronchodilator treatment to relieve symptoms and reduce exacerbations in adult patients with chronic obstructive pulmonary disease (COPD). | Patients with inhaler coordination problem. (Only applies to Primary Care settings) | One capsule inhalation daily. |